In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
In an unusual move, the board overseeing USAA's mutual funds is planning to replace its long-serving independent chairman with an interested chair upon completion of Victory ...
Half of the independent directors currently sitting on OppenheimerFunds' two boards will join an Invesco board later this year when Invesco's $5.7 billion acquisition of OppenheimerFunds ...
Many news reports have recounted how the partial government shutdown has affected government employees, shuttered national parks, and unsettled the stock market. But few, if any, ...
Richard Redeker has seen a lot in his 50 years in the mutual fund business, half of which he's spent as an independent director of what ...